Translation of pre-clinical studies into successful clinical trials for Alzheimer's disease: What are the roadblocks and how can they be overcome?

Journal of Alzheimer's Disease

Volumn 47, Issue 4, 2015, Pages 815-843

  Banik, Avijit ^a   Brown, Richard E ^b   Bamburg, James ^c   Lahiri, Debomoy K ^d   Khurana, Dheeraj ^a   Friedland, Robert P ^e   Chen, Wei ^f   Ding, Ying ^g   Mudher, Amritpal ^h   Padjen, Ante L ⁱ   Mukaetova Ladinska, Elizabeta ^j   Ihara, Masafumi ^k   Srivastava, Sudhir ^l   Srivastava, M V Padma ^m   Masters, Colin L ⁿ   Kalaria, Raj N ^j   Anand, Akshay ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

^b DALHOUSIE UNIVERSITY   (Canada)

^c Veterinary Dentistry and Oral Surgery   (United States)

^d INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e University of Louisville School of Medicine   (United States)

^f CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^g UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^h UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

ⁱ MCGILL UNIVERSITY   (Canada)

^j NEWCASTLE UNIVERSITY   (United Kingdom)

^k NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

^l CENTRAL DRUG RESEARCH INSTITUTE   (India)

^m ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

ⁿ UNIVERSITY OF MELBOURNE   (Australia)

more..

Author keywords

Alzheimer's disease; Animal model; Dementia; Memory disorder; Pre clinical; Treatment

Indexed keywords

ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN; CLIOQUINOL; DONEPEZIL; ELND 006; GALANTAMINE; HOMOTAURINE; MEMANTINE; MONOCLONAL ANTIBODY; NEUROTRANSMITTER; PBT 2; PONEZUMAB; QUINOLINE DERIVATIVE; RIVASTIGMINE; SEMAGACESTAT; TARENFLURBIL; UNCLASSIFIED DRUG;

ACTIVE IMMUNIZATION; ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; BLOOD BRAIN BARRIER; CLINICAL TRIAL (TOPIC); DISEASE ASSOCIATION; DRUG DEVELOPMENT; DRUG SCREENING; GENETICS; GENOMICS; GOOD CLINICAL PRACTICE; HUMAN; HYPOTHESIS; IMMUNOMODULATION; IMMUNOTHERAPY; METHODOLOGY; MULTICENTER STUDY (TOPIC); NEUROPATHOLOGY; NONHUMAN; PASSIVE IMMUNIZATION; PATHOPHYSIOLOGY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHYLOGENY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN FUNCTION; PUBLIC-PRIVATE PARTNERSHIP; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; RODENT MODEL; SCIENTIST; SPECIES DIVERSITY; STUDY DESIGN; ANIMAL; PROCEDURES; TRANSLATIONAL RESEARCH;

ALZHEIMER DISEASE; ANIMALS; CLINICAL TRIALS AS TOPIC; HUMANS; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84939438777     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-150136     Document Type: Review

References (261)

1. Reitz C, Brayne C, Mayeux R (2011) Epidemiology of Alzheimer disease. Nat Rev Neurol 7, 137-152.
2. Thies W, Bleiler L (2013) 2013 Alzheimer's disease facts and figures. Alzheimers Dement 9, 208-245.
3. Lobo A, Launer LJ, Fratiglioni L, Andersen K, Di Carlo A, Breteler MM, Copeland JR, Dartigues JF, Jagger C, Martinez-Lage J, Soininen H, Hofman A (2000) Prevalence of dementia and major subtypes in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 54, S4-9.
4. Kalaria RN, Maestre GE, Arizaga R, Friedland RP, Galasko D, Hall K, Luchsinger JA, Ogunniyi A, Perry EK, Potocnik F, Prince M, Stewart R, Wimo A, Zhang ZX, Antuono P, World Federation of Neurology Dementia ResearchG(2008) Alzheimer's disease and vascular dementia in developing countries: Prevalence, management, and risk factors. Lancet Neurol 7, 812-826.
5. Prince M, Bryce R, Albanese E, Wimo A, Ribeiro W, Ferri CP (2013) The global prevalence of dementia: A systematic review and metaanalysis. Alzheimers Dement 9, 63-75 e62.
6. Milne CP, Kaitin KI (2009) Translational medicine: An engine of change for bringing newtechnology to community health. Sci Transl Med 1, 5cm5.
7. National Cancer Institute, Report of the Translational Research Working Group of the National Cancer Advisory Board. Transforming Translation- Harnessing Discovery for Patient and Public Benefit, http://www. cancer. gov/about-nci/organization/ccct/about/trwgreport. pdf, Accessed June 10, 2015.
8. Sung NS, Crowley WF, Jr., Genel M, Salber P, Sandy L, Sherwood LM, Johnson SB, Catanese V, Tilson H, Getz K, Larson EL, Scheinberg D, Reece EA, Slavkin H, Dobs A, Grebb J, Martinez RA, Korn A, Rimoin D (2003) Central challenges facing the national clinical research enterprise. JAMA 289, 1278-1287.
9. Woolf SH (2008) The meaning of translational research and why it matters. JAMA 299, 211-213.
10. Becker RE, Greig NH (2013) Fire in the ashes: Can failed Alzheimer's disease drugs succeed with second chances? Alzheimers Dement 9, 50-57.
11. Saraf MK, Prabhakar S, Pandhi P, Anand A (2008) Bacopa monniera ameliorates amnesic effects of diazepam qualifying behavioral-molecular partitioning. Neuroscience 155, 476-484.
12. Saraf MK, Anand A, Prabhakar S (2010) Scopolamine induced amnesia is reversed by Bacopa monniera through participation of kinase-CREB pathway. Neurochem Res 35, 279-287.
13. Anand A, Saraf MK, Prabhakar S (2010) Antiamnesic effect of B. monniera on L-NNA induced amnesia involves calmodulin. Neurochem Res 35, 1172-1181.
14. Sun ZK, Yang HQ, Chen SD (2013) Traditional Chinese medicine: A promising candidate for the treatment of Alzheimer's disease. Transl Neurodegener 2, 6.
15. Nathan PJ, Clarke J, Lloyd J, Hutchison CW, Downey L, Stough C (2001) The acute effects of an extract of Bacopa monniera (Brahmi) on cognitive function in healthy normal subjects. Hum Psychopharmacol 16, 345-351.
16. Calabrese C, Gregory WL, Leo M, Kraemer D, Bone K, Oken B (2008) Effects of a standardized Bacopa monnieri extract on cognitive performance, anxiety, and depression in the elderly:Arandomized, double-blind, placebo-controlled trial. J Altern Complement Med 14, 707-713.
17. Downey LA, Kean J, Nemeh F, Lau A, Poll A, Gregory R, Murray M, Rourke J, Patak B, Pase MP, Zangara A, Lomas J, Scholey A, Stough C (2013) An acute, doubleblind, placebo-controlled crossover study of 320 mg and 640 mg doses of a special extract of Bacopa monnieri (CDRI 08) on sustained cognitive performance. Phytother Res 27, 1407-1413.
18. Ray B, Chauhan NB, Lahiri DK (2011) Oxidative insults to neurons and synapse are prevented by aged garlic extract and S-allyl-L-cysteine treatment in the neuronal culture and APP-Tg mouse model. J Neurochem 117, 388-402.
19. Ray B, Bisht S, Maitra A, Maitra A, Lahiri DK (2011) Neuroprotective and neurorescue effects of a novel polymeric nanoparticle formulation of curcumin (NanoCurc) in the neuronal cell culture and animal model: Implications for Alzheimer's disease. J Alzheimers Dis 23, 61-77.
20. Bent S (2008) Herbal medicine in the United States: Review of efficacy, safety, and regulation: Grand rounds at University of California, San Francisco Medical Center. J Gen Intern Med 23, 854-859.
21. Man SC, Durairajan SS, KumWF, Lu JH, Huang JD, Cheng CF, Chung V, Xu M, Li M (2008) Systematic review on the efficacy and safety of herbal medicines for Alzheimer's disease. J Alzheimers Dis 14, 209-223.
22. Markou A, Chiamulera C, Geyer MA, Tricklebank M, Steckler T (2009) Removing obstacles in neuroscience drug discovery: The future path for animal models. Neuropsychopharmacology 34, 74-89.
23. Macleod M, van der Worp HB (2010) Animal models of neurological disease: Are there any babies in the bathwater? Pract Neurol 10, 312-314.
24. van derWorp HB, HowellsDW, Sena ES, Porritt MJ, Rewell S, O'Collins V, Macleod MR (2010) Can animal models of disease reliably inform human studies? PLoS Med 7, e1000245.
25. Anand A, Banik A, Thakur K, Masters CL (2012) The animal models of dementia and Alzheimer's disease for preclinical testing and clinical translation. Curr Alzheimer Res 9, 1010-1029.
26. Gao J, Prough DS, McAdoo DJ, Grady JJ, Parsley MO, Ma L, Tarensenko YI, Wu P (2006) Transplantation of primed human fetal neural stem cells improves cognitive function in rats after traumatic brain injury. Exp Neurol 201, 281-292.
27. Tang J, Xu H, FanX, LiD, Rancourt D, Zhou G, Li Z,Yang L (2008) Embryonic stem cell-derived neural precursor cells improve memory dysfunction in Abeta(1-40) injured rats. Neurosci Res 62, 86-96.
28. Hyun DH, Mughal MR, Yang H, Lee JH, Ko EJ, Hunt ND, de Cabo R, MattsonMP(2010) The plasma membrane redox system is impaired by amyloid beta-peptide and in the hippocampus and cerebral cortex of 3xTgAD mice. Exp Neurol 225, 423-429.
29. Chin J (2011) Selecting a mouse model of Alzheimer's disease. Methods Mol Biol 670, 169-189.
30. Shineman DW, Basi GS, Bizon JL, Colton CA, Greenberg BD, Hollister BA, Lincecum J, Leblanc GG, Lee LB, Luo F, Morgan D, Morse I, Refolo LM, Riddell DR, Scearce-Levie K, Sweeney P, Yrjanheikki J, FillitHM(2011) Accelerating drug discovery for Alzheimer's disease: Best practices for preclinical animal studies. Alzheimers Res Ther 3, 28.
31. Guerreiro RJ, Hardy J (2011) Alzheimer's disease genetics: Lessons to improve disease modelling. Biochem Soc Trans 39, 910-916.
32. Pankevich DEWT, AltevogtBM(2013) Improving the Utility and Translation of Animal Models for Nervous System Disorders: Workshop Summary. National Academies Press (US), Washington, DC.
33. Lista S, Garaci FG, Ewers M, Teipel S, Zetterberg H, Blennow K, Hampel H (2014) CSF Abeta1-42 combined with neuroimaging biomarkers in the early detection, diagnosis and prediction of Alzheimer's disease. Alzheimers Dement 10, 381-392.
34. Engelborghs S, Le Bastard N (2012) The impact of cerebrospinal fluid biomarkers on the diagnosis of Alzheimer's disease. Mol Diagn Ther 16, 135-141.
35. Blennow K, Hampel H, Weiner M, Zetterberg H (2010) Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol 6, 131-144.
36. Henriksen K, O'Bryant SE, Hampel H, Trojanowski JQ, Montine TJ, Jeromin A, Blennow K, Lonneborg A, Wyss-Coray T, Soares H, Bazenet C, Sjogren M, Hu W, Lovestone S, Karsdal MA, Weiner MW, Blood-Based Biomarker Interest G (2014) The future of blood-based biomarkers for Alzheimer's disease. Alzheimers Dement 10, 115-131.
37. Shaffer JL, Petrella JR, Sheldon FC, Choudhury KR, Calhoun VD, Coleman RE, Doraiswamy PM, Alzheimer's Disease Neuroimaging I (2013) Predicting cognitive decline in subjects at risk for Alzheimer disease by using combined cerebrospinal fluid, MR imaging, and PET biomarkers. Radiology 266, 583-591.
38. Bakulski KM, Dolinoy DC, Sartor MA, Paulson HL, Konen JR, Lieberman AP, Albin RL, Hu H, Rozek LS (2012) Genome-wide DNA methylation differences between lateonset Alzheimer's disease and cognitively normal controls in human frontal cortex. J Alzheimers Dis 29, 571-588.
39. Bazenet C, Lovestone S (2012) Plasma biomarkers for Alzheimer's disease: Much needed but tough to find. Biomark Med 6, 441-454.
40. Teunissen CE, Verwey NA, Kester MI, van Uffelen K, Blankenstein MA (2010) Standardization of assay procedures for analysis of the CSF biomarkers amyloid beta((1-42)), tau, and phosphorylated tau in Alzheimer's disease: Report of an international workshop. Int J Alzheimers Dis 2010, pii: 635053.
41. Blennow K, Zetterberg H (2013) The application of cerebrospinal fluid biomarkers in early diagnosis of Alzheimer disease. Med Clin North Am 97, 369-376.
42. Schoonenboom NS, Reesink FE, Verwey NA, Kester MI, Teunissen CE, van de Ven PM, Pijnenburg YA, Blankenstein MA, Rozemuller AJ, Scheltens P, van der Flier WM (2012) Cerebrospinal fluid markers for differential dementia diagnosis in a large memory clinic cohort. Neurology 78, 47-54.
43. Koedam EL, van der Vlies AE, van der Flier WM, Verwey NA,Koene T, Scheltens P, Blankenstein MA, PijnenburgYA (2013) Cognitive correlates of cerebrospinal fluid biomarkers in frontotemporal dementia. Alzheimers Dement 9, 269-275.
44. Jonsson T, Atwal JK, Steinberg S, Snaedal J, Jonsson PV, Bjornsson S, Stefansson H, Sulem P, Gudbjartsson D, Maloney J, Hoyte K, Gustafson A, Liu Y, Lu Y, Bhangale T, Graham RR, Huttenlocher J, Bjornsdottir G, Andreassen OA, Jonsson EG, Palotie A, Behrens TW, Magnusson OT, Kong A, Thorsteinsdottir U,Watts RJ, Stefansson K (2012) A mutation in APP protects against Alzheimer's disease and age-related cognitive decline. Nature 488, 96-99.
45. Moore BD, Chakrabarty P, Levites Y, Kukar TL, Baine AM, Moroni T, Ladd TB, Das P, Dickson DW, Golde TE (2012) Overlapping profiles of Abeta peptides in the Alzheimer's disease and pathological aging brains. Alzheimers Res Ther 4, 18.
46. Galluzzi S, Geroldi C, Amicucci G, Bocchio-Chiavetto L, Bonetti M, Bonvicini C, Cotelli M, Ghidoni R, Paghera B, Zanetti O, Frisoni GB, Translational Outpatient Memory Clinic Working G (2013) Supporting evidence for using biomarkers in the diagnosis of MCI due to AD. J Neurol 260, 640-650.
47. McEvoy LK, Brewer JB (2012) Biomarkers for the clinical evaluation of the cognitively impaired elderly: Amyloid is not enough. Imaging Med 4, 343-357.
48. Greco I, Day N, Riddoch-Contreras J, Reed J, Soininen H, Kloszewska I, Tsolaki M, Vellas B, Spenger C, Mecocci P, Wahlund LO, Simmons A, Barnes J, Lovestone S (2012) Alzheimer's disease biomarker discovery using in silico literature mining and clinical validation. J Transl Med 10, 217.
49. Verwey NA, van der Flier WM, Blennow K, Clark C, Sokolow S, De Deyn PP, Galasko D, Hampel H, Hartmann T, Kapaki E, Lannfelt L, Mehta PD, Parnetti L, Petzold A, Pirttila T, Saleh L, Skinningsrud A, Swieten JC, Verbeek MM,Wiltfang J, Younkin S, Scheltens P, Blankenstein MA (2009) A worldwide multicentre comparison of assays for cerebrospinal fluid biomarkers in Alzheimer's disease. Ann Clin Biochem 46, 235-240.
50. Mattsson N, Andreasson U, Persson S, Arai H, Batish SD, Bernardini S, Bocchio-Chiavetto L, Blankenstein MA, Carrillo MC, Chalbot S, Coart E, Chiasserini D, Cutler N, Dahlfors G, Duller S, Fagan AM, Forlenza O, Frisoni GB, Galasko D, Galimberti D, Hampel H, Handberg A, Heneka MT, Herskovits AZ, Herukka SK, Holtzman DM, Humpel C, Hyman BT, Iqbal K, Jucker M, Kaeser SA, Kaiser E, Kapaki E, Kidd D, Klivenyi P, Knudsen CS, Kummer MP, Lui J, Llado A, Lewczuk P, Li QX, Martins R, Masters C, McAuliffe J, Mercken M, Moghekar A, Molinuevo JL, Montine TJ, Nowatzke W, O'Brien R, Otto M, Paraskevas GP, Parnetti L, Petersen RC, Prvulovic D, de Reus HP, Rissman RA, Scarpini E, Stefani A, Soininen H, Schroder J, Shaw LM, Skinningsrud A, Skrogstad B, Spreer A, Talib L, Teunissen C, Trojanowski JQ, Tumani H, Umek RM, Van Broeck B, Vanderstichele H, Vecsei L, Verbeek MM, Windisch M, Zhang J, Zetterberg H, Blennow K (2011) The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers. Alzheimers Dement 7, 386-395 e386.
51. Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, Bergstrom M, Savitcheva I, Huang GF, Estrada S, AusenB,DebnathML,BarlettaJ,PriceJC,SandellJ,Lopresti BJ,Wall A, Koivisto P, Antoni G, Mathis CA, Langstrom B (2004) Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 55, 306-319.
52. Doraiswamy PM, Sperling RA, Coleman RE, Johnson KA, Reiman EM, Davis MD, Grundman M, Sabbagh MN, Sadowsky CH, Fleisher AS, Carpenter A, Clark CM, Joshi AD, Mintun MA, Skovronsky DM, Pontecorvo MJ, Group AAS (2012) Amyloid-beta assessed by florbetapir F 18 PET and 18-month cognitive decline: A multicenter study. Neurology 79, 1636-1644.
53. Zannas AS, Doraiswamy PM, Shpanskaya KS, Murphy KR, Petrella JR, Burke JR, Wong TZ (2014) Impact of (18)F-florbetapir PET imaging of beta-amyloid neuritic plaque density on clinical decision-making. Neurocase 20, 466-473.
54. Sperling R, JohnsonK(2013) Biomarkers of Alzheimer disease: Current and future applications to diagnostic criteria. Continuum (Minneap Minn) 19, 325-338.
55. Lista S, Garaci FG, Toschi N, Hampel H (2013) Imaging epigenetics in Alzheimer's disease. Curr Pharm Des 19, 6393-6415.
56. Marques SC, Lemos R, Ferreiro E, Martins M, de Mendonca A, Santana I, Outeiro TF, Pereira CM (2012) Epigenetic regulation of BACE1 in Alzheimer's disease patients and in transgenic mice. Neuroscience 220, 256-266.
57. Reiman EM, Jagust WJ (2012) Brain imaging in the study of Alzheimer's disease. Neuroimage 61, 505-516.
58. Yang E, Farnum M, Lobanov V, Schultz T, Verbeeck R, RaghavanN, SamtaniMN,Novak G, NarayanV, DiBernardo A, Alzheimer's Disease Neuroimaging, Initiative (2011) Quantifying the pathophysiological timeline of Alzheimer's disease. J Alzheimers Dis 26, 745-753.
59. Jack CR Jr., Vemuri P, Wiste HJ, Weigand SD, Aisen PS, Trojanowski JQ, Shaw LM, Bernstein MA, Petersen RC, Weiner MW, Knopman DS, Alzheimer's Disease Neuroimaging I (2011) Evidence for ordering of Alzheimer disease biomarkers. Arch Neurol 68, 1526-1535.
60. Lo RY, Hubbard AE, Shaw LM, Trojanowski JQ, Petersen RC, Aisen PS, Weiner MW, Jagust WJ, Alzheimer's Disease Neuroimaging I (2011) Longitudinal change of biomarkers in cognitive decline. Arch Neurol 68, 1257-1266.
61. Arisi I, D'Onofrio M, Brandi R, Felsani A, Capsoni S, Drovandi G, Felici G,Weitschek E, Bertolazzi P, CattaneoA (2011) Gene expression biomarkers in the brain of a mouse model for Alzheimer's disease: Mining of microarray data by logic classification and feature selection. J Alzheimers Dis 24, 721-738.
62. Massoud F, Gauthier S (2010) Update on the pharmacological treatment of Alzheimer's disease. Curr Neuropharmacol 8, 69-80.
63. Jellinger KA (2009) Criteria for the neuropathological diagnosis of dementing disorders: Routes out of the swamp? Acta Neuropathol 117, 101-110.
64. Delrieu J, Ousset PJ, Caillaud C, Vellas B (2012) 'Clinical trials in Alzheimer's disease': Immunotherapy approaches. J Neurochem 120(Suppl 1), 186-193.
65. Gotz J, Ittner A, Ittner LM (2012) Tau-targeted treatment strategies in Alzheimer's disease. Br J Pharmacol 165, 1246-1259.
66. LemereCA(2009) Developing novel immunogens for a safe and effective Alzheimer's disease vaccine. Prog Brain Res 175, 83-93.
67. Dodart JC, Bales KR, Gannon KS, Greene SJ, DeMattos RB, Mathis C, DeLong CA, Wu S, Wu X, Holtzman DM, Paul SM (2002) Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. Nat Neurosci 5, 452-457.
68. Asuni AA, Boutajangout A, Quartermain D, Sigurdsson EM (2007) Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements. J Neurosci 27, 9115-9129.
69. Wang YJ (2014) Alzheimer disease: Lessons from immunotherapy for Alzheimer disease. Nat Rev Neurol 10, 188-189.
70. Liu YH, Giunta B, Zhou HD, Tan J, Wang YJ (2012) Immunotherapy for Alzheimer disease: The challenge of adverse effects. Nat Rev Neurol 8, 465-469.
71. Moriguchi S (2011) Pharmacological study on Alzheimer's drugs targeting calcium/calmodulin-dependent protein kinase II. J Pharmacol Sci 117, 6-11.
72. Ballatore C, Brunden KR, Huryn DM, Trojanowski JQ, Lee VM, Smith AB, 3rd (2012) Microtubule stabilizing agents as potential treatment for Alzheimer's disease and related neurodegenerative tauopathies. JMed Chem 55, 8979-8996.
73. Wyka J (2012) Nutritional factors in prevention of Alzheimer's disease. Rocz Panstw Zakl Hig 63, 135-140.
74. Castellani RJ, Perry G (2012) Pathogenesis and diseasemodifying therapy in Alzheimer's disease: The flat line of progress. Arch Med Res 43, 694-698.
75. Adlard PA, Cherny RA, Finkelstein DI, Gautier E, Robb E, Cortes M, Volitakis I, Liu X, Smith JP, Perez K, Laughton K, Li QX, Charman SA, Nicolazzo JA, Wilkins S, Deleva K, Lynch T, Kok G, Ritchie CW, Tanzi RE, Cappai R, Masters CL, Barnham KJ, Bush AI (2008) Rapid restoration of cognition in Alzheimer's transgenic mice with 8-hydroxy quinoline analogs is associated with decreased interstitial Abeta. Neuron 59, 43-55.
76. Faux NG, Ritchie CW, Gunn A, Rembach A, Tsatsanis A, Bedo J, Harrison J, Lannfelt L, Blennow K, Zetterberg H, Ingelsson M, Masters CL, Tanzi RE, Cummings JL, Herd CM, Bush AI (2010) PBT2 rapidly improves cognition in Alzheimer's Disease: Additional phase II analyses. J Alzheimers Dis 20, 509-516.
77. Lannfelt L, Blennow K, Zetterberg H, Batsman S, Ames D, Harrison J, Masters CL, Targum S, Bush AI, Murdoch R, Wilson J, Ritchie CW, group PEs (2008) Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: A phase IIa, double-blind, randomised, placebo-controlled trial. Lancet Neurol 7, 779-786.
78. Adlard PA, Bica L, White AR, Nurjono M, Filiz G, Crouch PJ, Donnelly PS, Cappai R, Finkelstein DI, Bush AI (2011) Metal ionophore treatment restores dendritic spine density and synaptic protein levels in a mouse model of Alzheimer's disease. PLoS One 6, e17669.
79. Gandy S, DeKosky ST (2013) Toward the treatment and prevention of Alzheimer's disease: Rational strategies and recent progress. Annu Rev Med 64, 367-383.
80. Bond M, Rogers G, Peters J, Anderson R, Hoyle M, Miners A, Moxham T, Davis S, Thokala P, Wailoo A, Jeffreys M, Hyde C (2012) The effectiveness and costeffectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of Technology Appraisal No. 111): A systematic review and economic model. Health Technol Assess 16, 1-470.
81. Rountree SD, Atri A, Lopez OL, Doody RS (2013) Effectiveness of antidementia drugs in delaying Alzheimer's disease progression. Alzheimers Dement 9, 338-345.
82. Pardridge WM (2009) Alzheimer's disease drug development and the problem of the blood-brain barrier. Alzheimers Dement 5, 427-432.
83. Di Stefano A, Iannitelli A, Laserra S, Sozio P (2011) Drug delivery strategies for Alzheimer's disease treatment. Expert Opin Drug Deliv 8, 581-603.
84. Desai BS, Monahan AJ, Carvey PM, Hendey B (2007) Blood-brain barrier pathology in Alzheimer's and Parkinson's disease: Implications for drug therapy. Cell Transplant 16, 285-299.
85. Kalaria RN (1992) The blood-brain barrier and cerebral microcirculation in Alzheimer disease. Cerebrovasc Brain Metab Rev 4, 226-260.
86. Blesa Gonzalez R, Boada Rovira M, Martinez Parra C, Gil-Saladie D, Almagro CA, Gobartt Vazquez AL, en representacion del grupo de investigadores del estudio k APA (2011) Evaluation of the convenience of changing the rivastigmine administration route in patients with Alzheimer disease. Neurologia 26, 262-271.
87. Lou G, Zhang Q, Xiao F, Xiang Q, Su Z, Zhang L, Yang P, Yang Y, Zheng Q, Huang Y (2012) Intranasal administration of TAT-haFGF((1)(4)(-)(1)(5)(4)) attenuates disease progression in a mouse model of Alzheimer's disease. Neuroscience 223, 225-237.
88. Cook AM, Mieure KD, Owen RD, Pesaturo AB, Hatton J (2009) Intracerebroventricular administration of drugs. Pharmacotherapy 29, 832-845.
89. Freiherr J, Hallschmid M, Frey WH, 2nd, Brunner YF, Chapman CD, Holscher C, Craft S, De Felice FG, Benedict C (2013) Intranasal insulin as a treatment for Alzheimer's disease: A review of basic research and clinical evidence. CNS Drugs 27, 505-514.
90. Holscher C (2014) First clinical data of the neuroprotective effects of nasal insulin application in patients with Alzheimer's disease. Alzheimers Dement 10, S33-S37.
91. Mandel RJ (2010) CERE-110, an adeno-associated virusbased gene delivery vector expressing human nerve growth factor for the treatment of Alzheimer's disease. Curr Opin Mol Ther 12, 240-247.
92. Overk CR, Borgia JA, Mufson EJ (2011) A novel approach for long-term oral drug administration in animal research. J Neurosci Methods 195, 194-199.
93. Lewis H, Beher D, Cookson N, OakleyA, Piggott M, Morris CM, Jaros E, Perry R, Ince P,Kenny RA, Ballard CG, Shearman MS, Kalaria RN (2006) Quantification of Alzheimer pathology in ageing and dementia: Age-related accumulation of amyloid-beta(42) peptide in vascular dementia. Neuropathol Appl Neurobiol 32, 103-118.
94. Prusiner SB (2012) Cell biology. A unifying role for prions in neurodegenerative diseases. Science 336, 1511-1513.
95. Lahiri DK (2012) Prions: A piece of the puzzle? Science 337, 1172.
96. Tomiyama T, Nagata T, Shimada H, Teraoka R, Fukushima A, Kanemitsu H, Takuma H, Kuwano R, ImagawaM, Ataka S, Wada Y, Yoshioka E, Nishizaki T, Watanabe Y, Mori H (2008)Anewamyloid beta variant favoring oligomerization in Alzheimer's-type dementia. Ann Neurol 63, 377-387.
97. Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, Smith I, Brett FM, Farrell MA, Rowan MJ, Lemere CA, Regan CM,Walsh DM, Sabatini BL, Selkoe DJ (2008) Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med 14, 837-842.
98. Mc Donald JM, Savva GM, Brayne C, Welzel AT, Forster G, Shankar GM, Selkoe DJ, Ince PG, Walsh DM, Medical Research Council Cognitive F, Ageing S (2010) The presence of sodium dodecyl sulphate-stable Abeta dimers is strongly associated with Alzheimer-type dementia. Brain 133, 1328-1341.
99. Miura T, Suzuki K, Kohata N, Takeuchi H (2000) Metal binding modes of Alzheimer's amyloid beta-peptide in insoluble aggregates and soluble complexes. Biochemistry 39, 7024-7031.
100. Feaga HA, Maduka RC, Foster MN, Szalai VA (2011) Affinity of Cu+ for the copper-binding domain of the amyloid-beta peptide of Alzheimer's disease. Inorg Chem 50, 1614-1618.
101. Bellingham SA, Lahiri DK, Maloney B, La Fontaine S, Multhaup G, Camakaris J (2004) Copper depletion down-regulates expression of the Alzheimer's disease amyloid-beta precursor protein gene. J Biol Chem 279, 20378-20386.
102. Ansari MA, Scheff SW (2010) Oxidative stress in the progression of Alzheimer disease in the frontal cortex. J Neuropathol Exp Neurol 69, 155-167.
103. O'Brien RJ, Resnick SM, Zonderman AB, Ferrucci L, Crain BJ, Pletnikova O, Rudow G, Iacono D, Riudavets MA, Driscoll I, Price DL, Martin LJ, Troncoso JC (2009) Neuropathologic studies of the Baltimore Longitudinal Study of Aging (BLSA). J Alzheimers Dis 18, 665-675.
104. Edrey YH, Medina DX, Gaczynska M, Osmulski PA, Oddo S, Caccamo A, Buffenstein R (2013) Amyloid beta and the longest-lived rodent: The naked mole-rat as a model for natural protection from Alzheimer's disease. Neurobiol Aging 34, 2352-2360.
105. Cleary JP, Walsh DM, Hofmeister JJ, Shankar GM, Kuskowski MA, Selkoe DJ, Ashe KH (2005) Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat Neurosci 8, 79-84.
106. Benilova I, De Strooper B (2013) Neuroscience. Promiscuous Alzheimer's amyloid: Yet another partner. Science 341, 1354-1355.
107. Hong L, Carducci TM, Bush WD, Dudzik CG, Millhauser GL, Simon JD (2010) Quantification of the binding properties of Cu2+ to the amyloid beta peptide: Coordination spheres for human and rat peptides and implication on Cu2+-induced aggregation. J Phys Chem B 114, 11261-11271.
108. Lauren J, Gimbel DA, Nygaard HB, Gilbert JW, Strittmatter SM (2009) Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers. Nature 457, 1128-1132.
109. Kim T, Vidal GS, Djurisic M, William CM, Birnbaum ME, Garcia KC, Hyman BT, Shatz CJ (2013) Human LilrB2 is a beta-amyloid receptor and its murine homolog PirB regulates synaptic plasticity in an Alzheimer's model. Science 341, 1399-1404.
110. Um JW, Kaufman AC, Kostylev M, Heiss JK, Stagi M, Takahashi H, Kerrisk ME, Vortmeyer A, Wisniewski T, Koleske AJ, Gunther EC, Nygaard HB, Strittmatter SM (2013) Metabotropic glutamate receptor 5 is a coreceptor for Alzheimer abeta oligomer bound to cellular prion protein. Neuron 79, 887-902.
111. Malthankar-Phatak GH, Lin YG, Giovannone N, Siman R (2012) Amyloid deposition and advanced age fails to induce Alzheimer's type progression in a double knock-in mouse model. Aging Dis 3, 141-155.
112. Kim J, Chakrabarty P, Hanna A, March A, Dickson DW, Borchelt DR, Golde T, Janus C (2013) Normal cognition in transgenic BRI2-Abeta mice. Mol Neurodegener 8, 15.
113. Seabrook GR, Ray WJ, Shearman M, Hutton M (2007) Beyond amyloid: The next generation of Alzheimer's disease therapeutics. Mol Interv 7, 261-270.
114. Herrup K, Carrillo MC, Schenk D, Cacace A, Desanti S, Fremeau R, Bhat R, Glicksman M, May P, Swerdlow R, Van Eldik LJ, Bain LJ, Budd S (2013) Beyond amyloid: Getting real about nonamyloid targets in Alzheimer's disease. Alzheimers Dement 9, 452-458 e451.
115. Griffin WS, Barger SW (2010) Neuroinflammatory cytokines-the common thread in Alzheimer's pathogenesis. US Neurol 6, 19-27.
116. Minamide LS, Striegl AM, Boyle JA, Meberg PJ, Bamburg JR (2000) Neurodegenerative stimuli induce persistent ADF/cofilin-actin rods that disrupt distal neurite function. Nat Cell Biol 2, 628-636.
117. Sudduth TL, Schmitt FA, Nelson PT, Wilcock DM (2013) Neuroinflammatory phenotype in early Alzheimer's disease. Neurobiol Aging 34, 1051-1059.
118. Minamide LS, Maiti S, Boyle JA, Davis RC, Coppinger JA, Bao Y, Huang TY, Yates J, Bokoch GM, Bamburg JR (2010) Isolation and characterization of cytoplasmic cofilin-actin rods. J Biol Chem 285, 5450-5460.
119. Bernstein BW, Shaw AE, Minamide LS, Pak CW, Bamburg JR (2012) Incorporation of cofilin into rods depends on disulfide intermolecular bonds: Implications for actin regulation and neurodegenerative disease. J Neurosci 32, 6670-6681.
120. Maloney MT, Minamide LS, Kinley AW, Boyle JA, Bamburg JR (2005) Beta-secretase-cleaved amyloid precursor protein accumulates at actin inclusions induced in neurons by stress or amyloid beta: A feedforward mechanism for Alzheimer's disease. J Neurosci 25, 11313-11321.
121. Zhao L,MaQL, Calon F, Harris-White ME,Yang F, LimGP, Morihara T, Ubeda OJ, Ambegaokar S, Hansen JE,Weisbart RH, Teter B, Frautschy SA, Cole GM (2006) Role of p21-activated kinase pathway defects in the cognitive deficits of Alzheimer disease. Nat Neurosci 9, 234-242.
122. Yao J, Hennessey T, Flynt A, Lai E, BealMF, LinMT(2010) MicroRNA-related cofilin abnormality in Alzheimer's disease. PLoS One 5, e15546.
123. Jacob CP, Koutsilieri E, Bartl J, Neuen-Jacob E, Arzberger T, Zander N, Ravid R, Roggendorf W, Riederer P, Grunblatt E (2007) Alterations in expression of glutamatergic transporters and receptors in sporadic Alzheimer's disease. J Alzheimers Dis 11, 97-116.
124. Cichon J, Sun C, Chen B, Jiang M, Chen XA, SunY,WangY, Chen G (2012) Cofilin aggregation blocks intracellular trafficking and induces synaptic loss in hippocampal neurons. J Biol Chem 287, 3919-3929.
125. Gu J, Lee CW, Fan Y, Komlos D, Tang X, Sun C, Yu K, Hartzell HC, Chen G, Bamburg JR, Zheng JQ (2010) ADF/cofilin-mediated actin dynamics regulate AMPA receptor trafficking during synaptic plasticity. Nat Neurosci 13, 1208-1215.
126. Davis RC, Marsden IT, Maloney MT, Minamide LS, Podlisny M, Selkoe DJ, Bamburg JR (2011) Amyloid beta dimers/trimers potently induce cofilin-actin rods that are inhibited by maintaining cofilin-phosphorylation. Mol Neurodegener 6, 10.
127. Maloney MT, Bamburg JR (2007) Cofilin-mediated neurodegeneration in Alzheimer's disease and other amyloidopathies. Mol Neurobiol 35, 21-44.
128. Walsh KP, Minamide LS, Kane SJ, Shaw AE, Brown DR, Pulford B, Zabel MD, Lambeth JD, Kuhn TB, Bamburg JR (2014) Amyloid-beta and proinflammatory cytokines utilize a prion protein-dependent pathway to activate NADPH oxidase and induce cofilin-actin rods in hippocampal neurons. PLoS One 9, e95995.
129. Van Dam D, De Deyn PP (2011) Animal models in the drug discovery pipeline for Alzheimer's disease. Br J Pharmacol 164, 1285-1300.
130. Bonner JM, Boulianne GL (2011) Drosophila as a model to study age-related neurodegenerative disorders: Alzheimer's disease. Exp Gerontol 46, 335-339.
131. Calahorro F, Ruiz-Rubio M (2011) Caenorhabditis elegans as an experimental tool for the study of complex neurological diseases: Parkinson's disease, Alzheimer's disease and autism spectrum disorder. Invert Neurosci 11, 73-83.
132. Newman M, Verdile G, Martins RN, Lardelli M (2011) Zebrafish as a tool in Alzheimer's disease research. Biochim Biophys Acta 1812, 346-352.
133. Hall AM, Roberson ED (2012) Mouse models of Alzheimer's disease. Brain Res Bull 88, 3-12.
134. Benedikz E, Kloskowska E,Winblad B (2009) The rat as an animal model of Alzheimer's disease. J Cell Mol Med 13, 1034-1042.
135. Heuer E, Rosen RF, Cintron A, Walker LC (2012) Nonhuman primate models of Alzheimer-like cerebral proteopathy. Curr Pharm Des 18, 1159-1169.
136. Ndung'u M, Hartig W, Wegner F, Mwenda JM, Low RW, Akinyemi RO, Kalaria RN (2012) Cerebral amyloid beta(42) deposits and microvascular pathology in ageing baboons. Neuropathol Appl Neurobiol 38, 487-499.
137. Bales KR (2012) The value and limitations of transgenic mouse models used in drug discovery for Alzheimer's disease: An update. Expert Opin Drug Discov 7, 281-297.
138. LaFerla FM, GreenKN(2012) Animal models of Alzheimer disease. Cold Spring Harb Perspect Med 2, pii: a006320.
139. Alzforum, http://www. alzforum. org/research-models/ searchresearch-model-name=3Tg&research-model-name =tau#results, Accessed June 10, 2015.
140. Maruyama M, Shimada H, Suhara T, Shinotoh H, Ji B, Maeda J, Zhang MR, Trojanowski JQ, Lee VM, Ono M, Masamoto K, Takano H, Sahara N, Iwata N, Okamura N, Furumoto S, Kudo Y, Chang Q, Saido TC, Takashima A, Lewis J, Jang MK, Aoki I, Ito H, Higuchi M (2013) Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls. Neuron 79, 1094-1108.
141. Troquier L, Caillierez R, Burnouf S, Fernandez-Gomez FJ, Grosjean ME, Zommer N, Sergeant N, Schraen-Maschke S, Blum D, Buee L (2012) Targeting phospho-Ser422 by active Tau Immunotherapy in the THYTau22 mouse model: Asuitable therapeutic approach. Curr Alzheimer Res 9, 397-405.
142. Schauwecker PE (2011) The relevance of individual genetic background and its role in animal models of epilepsy. Epilepsy Res 97, 1-11.
143. Linder CC (2001) The influence of genetic background on spontaneous and genetically engineered mouse models of complex diseases. Lab Anim (NY) 30, 34-39.
144. O'Leary TP, Gunn RK, Brown RE (2013) What are we measuring when we test strain differences in anxiety in mice? Behav Genet 43, 34-50.
145. An XL, Zou JX, Wu RY, Yang Y, Tai FD, Zeng SY, Jia R, Zhang X, Liu EQ, Broders H (2011) Strain and sex differences in anxiety-like and social behaviors in C57BL/6J and BALB/cJ mice. Exp Anim 60, 111-123.
146. Arendash GW, King DL, Gordon MN, Morgan D, Hatcher JM, Hope CE, DiamondDM(2001) Progressive, age-related behavioral impairments in transgenic mice carrying both mutant amyloid precursor protein and presenilin-1 transgenes. Brain Res 891, 42-53.
147. Luo F, Rustay NR, Ebert U, Hradil VP, Cole TB, Llano DA, Mudd SR, Zhang Y, Fox GB, Day M (2012) Characterization of 7-and 19-month-old Tg2576 mice using multimodal in vivo imaging: Limitations as a translatable model of Alzheimer's disease. Neurobiol Aging 33, 933-944.
148. Pallas M, Camins A, Smith MA, Perry G, Lee HG, Casadesus G (2008) From aging to Alzheimer's disease: Unveiling "the switch" with the senescence-accelerated mouse model (SAMP8). J Alzheimers Dis 15, 615-624.
149. McCarthy MM, Arnold AP, Ball GF, Blaustein JD, De Vries GJ (2012) Sex differences in the brain: The not so inconvenient truth. J Neurosci 32, 2241-2247.
150. YueM, Hanna A,Wilson J, Roder H, JanusC(2011) Sex difference in pathology and memory decline in rTg4510 mouse model of tauopathy. Neurobiol Aging 32, 590-603.
151. Palanza P, Gioiosa L, Parmigiani S (2001) Social stress in mice: Gender differences and effects of estrous cycle and social dominance. Physiol Behav 73, 411-420.
152. Calkosinski I, Dobrzynski M, Kobierska-Brzoza J, Majda J, Szymonowicz M, Calkosinska M, Dzierzba K, Bronowicka-SzydelkoA, Soltan E, Seweryn E, Zasadowski A, GamianA (2010) The influence of strain, sex and age on selected biochemical parameters in blood serum of Buffalo and Wistar rats. Pol J Vet Sci 13, 293-299.
153. Beery AK, Zucker I (2011) Sex bias in neuroscience and biomedical research. Neurosci Biobehav Rev 35, 565-572.
154. Downes EC, Robson J, Grailly E, Abdel-All Z, Xuereb J, Brayne C, Holland A, Honer WG,Mukaetova-Ladinska EB (2008) Loss of synaptophysin and synaptosomal-associated protein 25-kDa (SNAP-25) in elderly Down syndrome individuals. Neuropathol Appl Neurobiol 34, 12-22.
155. O'Dwyer L, Lamberton F, Bokde AL, Ewers M, Faluyi YO, Tanner C, Mazoyer B, O'Neill D, Bartley M, Collins R, Coughlan T, Prvulovic D, Hampel H (2012) Sexual dimorphism in healthy aging and mild cognitive impairment: A DTI study. PLoS One 7, e37021.
156. Bergmann S, Ihmels J, Barkai N (2004) Similarities and differences in genome-wide expression data of six organisms. PLoS Biol 2, E9.
157. Reagan-Shaw S, Nihal M, Ahmad N (2008) Dose translation from animal to human studies revisited. FASEB J 22, 659-661.
158. Tsaparas P, Marino-Ramirez L, Bodenreider O, Koonin EV, Jordan IK (2006) Global similarity and local divergence in human and mouse gene co-expression networks. BMC Evol Biol 6, 70.
159. Miller JA, Horvath S, Geschwind DH (2010) Divergence of human and mouse brain transcriptome highlights Alzheimer disease pathways. Proc Natl Acad Sci U S A 107, 12698-12703.
160. Behrendt G, Baer K, Buffo A, Curtis MA, Faull RL, Rees MI, Gotz M, Dimou L (2013) Dynamic changes in myelin aberrations and oligodendrocyte generation in chronic amyloidosis in mice and men. Glia 61, 273-286.
161. Zheng-Bradley X, Rung J, Parkinson H, Brazma A (2010) Large scale comparison of global gene expression patterns in human and mouse. Genome Biol 11, R124.
162. Yu S, Zheng L, Li Y, Li C, Ma C, Li Y, Li X, Hao P (2012) A cross-species analysis method to analyze animal models' similarity to human's disease state. BMC Syst Biol 6 Suppl 3, S18.
163. Tan PP, French L, Pavlidis P (2013) Neuron-enriched gene expression patterns are regionally anti-correlated with oligodendrocyte-enriched patterns in the adult mouse and human brain. Front Neurosci 7, 5.
164. Perl DP (2010) Neuropathology of Alzheimer's disease. Mt Sinai J Med 77, 32-42.
165. McDonald JM, Cairns NJ, Taylor-Reinwald L, Holtzman D,Walsh DM (2012) The levels of water-soluble and tritonsoluble Abeta are increased in Alzheimer's disease brain. Brain Res 1450, 138-147.
166. Tomiyama T, Matsuyama S, Iso H, Umeda T, Takuma H, Ohnishi K, Ishibashi K, Teraoka R, Sakama N, Yamashita T, Nishitsuji K, Ito K, Shimada H, Lambert MP, Klein WL, Mori H (2010) A mouse model of amyloid beta oligomers: Their contribution to synaptic alteration, abnormal tau phosphorylation, glial activation, and neuronal loss in vivo. J Neurosci 30, 4845-4856.
167. Braidy N, Munoz P, Palacios AG, Castellano-Gonzalez G, Inestrosa NC, Chung RS, Sachdev P, Guillemin GJ (2012) Recent rodent models for Alzheimer's disease: Clinical implications and basic research. J Neural Transm 119, 173-195.
168. Eriksen JL, Janus CG (2007) Plaques, tangles, and memory loss in mouse models of neurodegeneration. Behav Genet 37, 79-100.
169. Duyckaerts C, Potier MC, Delatour B (2008) Alzheimer disease models and human neuropathology: Similarities and differences. Acta Neuropathol 115, 5-38.
170. Amadoro G, Corsetti V, Atlante A, Florenzano F, Capsoni S, Bussani R, Mercanti D, Calissano P (2012) Interaction between NH(2)-tau fragment and Abeta in Alzheimer's disease mitochondria contributes to the synaptic deterioration. Neurobiol Aging 33, 833 e831-825.
171. Povova J, Ambroz P, Bar M, PavukovaV, Sery O,Tomaskova H, Janout V (2012) Epidemiological of and risk factors for Alzheimer's disease: A review. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 156, 108-114.
172. Friedland RP, Brayne C (2009) What does the pediatrician need to knowabout Alzheimer disease? JDev Behav Pediatr 30, 239-241.
173. Friedland RP, Nandi S (2013) A modest proposal for a longitudinal study of dementia prevention (with apologies to Jonathan Swift, 1729). J Alzheimers Dis 33, 313-315.
174. Lindsay J, Laurin D, Verreault R, Hebert R, Helliwell B, Hill GB, McDowell I (2002) Risk factors for Alzheimer's disease: A prospective analysis from the Canadian Study of Health and Aging. Am J Epidemiol 156, 445-453.
175. Polidori MC, Pientka L, Mecocci P (2012) A review of the major vascular risk factors related to Alzheimer's disease. J Alzheimers Dis 32, 521-530.
176. SivanandamTM,ThakurMK(2012)Traumatic brain injury: A risk factor for Alzheimer's disease. Neurosci Biobehav Rev 36, 1376-1381.
177. Behl C (2012) Brain aging and late-onset Alzheimer's disease: Many open questions. Int Psychogeriatr 24(Suppl 1), S3-S9.
178. Norton MC, Dew J, Smith H, Fauth E, Piercy KW, Breitner JC, Tschanz J, Wengreen H, Welsh-Bohmer K (2012) Lifestyle behavior pattern is associated with different levels of risk for incident dementia and Alzheimer's disease: The Cache County study. J Am Geriatr Soc 60, 405-412.
179. Barnes DE,YaffeK(2011) The projected effect of risk factor reduction on Alzheimer's disease prevalence. Lancet Neurol 10, 819-828.
180. Schindowski K, Kratzsch T, Peters J, Steiner B, Leutner S, Touchet N, Maurer K, Czech C, Pradier L, Frolich L, Muller WE, EckertA(2003) Impact of aging: Sporadic, and genetic risk factors on vulnerability to apoptosis in Alzheimer's disease. Neuromolecular Med 4, 161-178.
181. Zhuo JM, Pratico D (2010) Acceleration of brain amyloidosis in an Alzheimer's disease mouse model by a folate, vitamin B6 and B12-deficient diet. Exp Gerontol 45, 195-201.
182. Nishio K, Ihara M, Yamasaki N, Kalaria RN, Maki T, Fujita Y, Ito H, Oishi N, Fukuyama H, Miyakawa T, Takahashi R, Tomimoto H (2010) A mouse model characterizing features of vascular dementia with hippocampal atrophy. Stroke 41, 1278-1284.
183. Belinson H, Michaelson DM (2009) Pathological synergism between amyloid-beta and apolipoprotein E4-the most prevalent yet understudied genetic risk factor for Alzheimer's disease. J Alzheimers Dis 17, 469-481.
184. Seripa D, D'Onofrio G, Panza F, Cascavilla L, Masullo C, PilottoA(2011) The genetics of the human APOE polymorphism. Rejuvenation Res 14, 491-500.
185. Takeda S, Sato N, Uchio-Yamada K, Sawada K, Kunieda T, Takeuchi D, Kurinami H, Shinohara M, Rakugi H, Morishita R (2010) Diabetes-accelerated memory dysfunction via cerebrovascular inflammation and Abeta deposition in an Alzheimer mouse model with diabetes. Proc Natl Acad Sci U S A 107, 7036-7041.
186. Devi L, Alldred MJ, Ginsberg SD, Ohno M (2012) Mechanisms underlying insulin deficiency-induced acceleration of beta-amyloidosis in a mouse model of Alzheimer's disease. PLoS One 7, e32792.
187. Mattsson N, Zetterberg H, Hansson O, Andreasen N, Parnetti L, Jonsson M, Herukka SK, van der Flier WM, Blankenstein MA, Ewers M, Rich K, Kaiser E, Verbeek M, Tsolaki M, Mulugeta E, Rosen E, Aarsland D, Visser PJ, Schroder J, Marcusson J, de Leon M, Hampel H, Scheltens P, Pirttila T,Wallin A, Jonhagen ME, Minthon L,Winblad B, BlennowK(2009) CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA 302, 385-393.
188. Arab L, Sabbagh MN (2010) Are certain lifestyle habits associated with lower Alzheimer's disease risk? J Alzheimers Dis 20, 785-794.
189. Maesako M, Uemura K, Kubota M, Kuzuya A, Sasaki K, Hayashida N, Asada-Utsugi M, Watanabe K, Uemura M, Kihara T, Takahashi R, Shimohama S, Kinoshita A (2012) Exercise is more effective than diet control in preventing high fat diet-induced beta-amyloid deposition and memory deficit in amyloid precursor protein transgenic mice. J Biol Chem 287, 23024-23033.
190. Akinyemi RO,Mukaetova-Ladinska EB, Attems J, Ihara M, Kalaria RN (2013) Vascular risk factors and neurodegeneration in ageing related dementias: Alzheimer's disease and vascular dementia. Curr Alzheimer Res 10, 642-653.
191. Fratiglioni L, Paillard-Borg S, Winblad B (2004) An active and socially integrated lifestyle in late life might protect against dementia. Lancet Neurol 3, 343-353.
192. Paillard-Borg S, Fratiglioni L, XuW,Winblad B,Wang HX (2012) An active lifestyle postpones dementia onset by more than one year in very old adults. J Alzheimers Dis 31, 835-842.
193. Flicker L (2009) Life style interventions to reduce the risk of dementia. Maturitas 63, 319-322.
194. Merrill DA, Small GW (2011) Prevention in psychiatry: Effects of healthy lifestyle on cognition. Psychiatr Clin North Am 34, 249-261.
195. Basha MR, Wei W, Bakheet SA, Benitez N, Siddiqi HK, Ge YW, Lahiri DK, Zawia NH (2005) The fetal basis of amyloidogenesis: Exposure to lead and latent overexpression of amyloid precursor protein and beta-amyloid in the aging brain. J Neurosci 25, 823-829.
196. Lahiri DK, Maloney B, Zawia NH (2009) The LEARn model: An epigenetic explanation for idiopathic neurobiological diseases. Mol Psychiatry 14, 992-1003.
197. Miller DB, O'Callaghan JP (2008) Do early-life insults contribute to the late-life development of Parkinson and Alzheimer diseases? Metabolism 57(Suppl 2), S44-S49.
198. Bolin CM, Basha R, Cox D, Zawia NH, Maloney B, Lahiri DK, Cardozo-Pelaez F (2006) Exposure to lead and the developmental origin of oxidativeDNAdamage in the aging brain. FASEB J 20, 788-790.
199. Maloney B, Sambamurti K, Zawia N, Lahiri DK (2012) Applying epigenetics to Alzheimer's disease via the latent early-life associated regulation (LEARn) model. Curr Alzheimer Res 9, 589-599.
200. Wu J, Basha MR, Brock B, Cox DP, Cardozo-Pelaez F, McPherson CA, Harry J, Rice DC, Maloney B, Chen D, Lahiri DK, Zawia NH (2008) Alzheimer's disease (AD)-like pathology in aged monkeys after infantile exposure to environmental metal lead (Pb): Evidence for a developmental origin and environmental link for AD. J Neurosci 28, 3-9.
201. Kozauer N, Katz R (2013) Regulatory innovation and drug development for early-stage Alzheimer's disease. N Engl J Med 368, 1169-1171.
202. Sarazin M, de Souza LC, Lehericy S, Dubois B (2012) Clinical and research diagnostic criteria for Alzheimer's disease. Neuroimaging Clin N Am 22, 23-32,viii.
203. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, Klunk WE, Koroshetz WJ, Manly JJ, Mayeux R, Mohs RC, Morris JC, Rossor MN, Scheltens P, Carrillo MC, Thies B, Weintraub S, Phelps CH (2011) The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7, 263-269.
204. Castellani RJ, Rolston RK, Smith MA (2010) Alzheimer disease. Dis Mon 56, 484-546.
205. Schellinck HM CD, Brown RE (2010) How many ways can mouse behavioral experiments go wrong? Confounding variables in mouse models of neurodegenerative diseases and how to control them. In Advances in the Study of Behavior, Brockmann HJ, ed. Burlington: Academic Press, Burlington, pp. 255-366.
206. Brown RE (2012) Improving animal models for nervous system disorders. Genes Brain Behav 11, 753-756.
207. Wong AA, Brown RE (2006) Visual detection, pattern discrimination and visual acuity in 14 strains of mice. Genes Brain Behav 5, 389-403.
208. Wong AA, Brown RE (2007) Age-related changes in visual acuity, learning and memory in C57BL/6J andDBA/2J mice. Neurobiol Aging 28, 1577-1593.
209. Yan QJ, Asafo-Adjei PK, Arnold HM, Brown RE, BauchwitzRP( 2004)Aphenotypic and molecular characterization of the fmr1-tm1Cgr fragile X mouse. Genes Brain Behav 3, 337-359.
210. Yassine N, Lazaris A, Dorner-Ciossek C, Despres O, Meyer L, Maitre M, Mensah-Nyagan AG, Cassel JC, Mathis C (2013) Detecting spatial memory deficits beyond blindness in tg2576 Alzheimer mice. Neurobiol Aging 34, 716-730.
211. Laber K, Veatch LM, Lopez MF, Mulligan JK, Lathers DM (2008) Effects of housing density on weight gain, immune function, behavior, and plasma corticosterone concentrations in BALB/c and C57BL/6 mice. J Am Assoc Lab Anim Sci 47, 16-23.
212. Nicholson A, Malcolm RD, Russ PL, Cough K, Touma C, Palme R, Wiles MV (2009) The response of C57BL/6J and BALB/cJ mice to increased housing density. J Am Assoc Lab Anim Sci 48, 740-753.
213. Banik A, Anand A (2011) Loss of learning in mice when exposed to rat odor: A water maze study. Behav Brain Res 216, 466-471.
214. Martin AL, Brown RE (2010) The lonely mouse: Verification of a separation-induced model of depression in female mice. Behav Brain Res 207, 196-207.
215. O'Leary TP, Brown RE (2012) The effects of apparatus design and test procedure on learning and memory performance of C57BL/6J mice on the Barnes maze. J Neurosci Methods 203, 315-324.
216. O'Leary TP, Brown RE (2013) Optimization of apparatus design and behavioral measures for the assessment of visuospatial learning and memory of mice on the Barnes maze. Learn Mem 20, 85-96.
217. Landis SC, Amara SG, Asadullah K, Austin CP, Blumenstein R, Bradley EW, Crystal RG, Darnell RB, Ferrante RJ, Fillit H, Finkelstein R, Fisher M, Gendelman HE, Golub RM, Goudreau JL, Gross RA, Gubitz AK, Hesterlee SE, Howells DW, Huguenard J, Kelner K, KoroshetzW, Krainc D, Lazic SE, Levine MS,Macleod MR, McCall JM, Moxley RT, 3rd, Narasimhan K, Noble LJ, Perrin S, Porter JD, Steward O, Unger E, Utz U, Silberberg SD (2012) A call for transparent reporting to optimize the predictive value of preclinical research. Nature 490, 187-191.
218. Sena ES, van derWorp HB, Bath PM,HowellsDW,Macleod MR(2010) Publication bias in reports of animal stroke studies leads to major overstatement of efficacy. PLoS Biol 8, e1000344.
219. ter Riet G, Korevaar DA, Leenaars M, Sterk PJ, Van Noorden CJ, Bouter LM, Lutter R, Elferink RP, Hooft L (2012) Publication bias in laboratory animal research: A survey on magnitude, drivers, consequences and potential solutions. PLoS One 7, e43404.
220. Sutherland BA, Minnerup J, Balami JS, Arba F, Buchan AM, Kleinschnitz C (2012) Neuroprotection for ischaemic stroke:Translation from the bench to the bedside. Int J Stroke 7, 407-418.
221. Bebarta V, Luyten D, Heard K (2003) Emergency medicine animal research: Does use of randomization and blinding affect the results? Acad Emerg Med 10, 684-687.
222. Kilkenny C, Parsons N, Kadyszewski E, FestingMF, Cuthill IC, Fry D, Hutton J, AltmanDG(2009) Survey of the quality of experimental design, statistical analysis and reporting of research using animals. PLoS One 4, e7824.
223. Hess KR (2011) Statistical design considerations in animal studies published recently in cancer research. Cancer Re 71, 625.
224. Altman DG (1996) Better reporting of randomised controlled trials: The CONSORT statement. BMJ 313, 570-571.
225. Kilkenny C, Browne WJ, Cuthill IC, Emerson M, Altman DG (2010) Improving bioscience research reporting: The ARRIVE guidelines for reporting animal research. PLoS Biol 8, e1000412.
226. Crusio WE, Goldowitz D, Holmes A,WolferD(2009) Standards for the publication of mouse mutant studies. Genes Brain Behav 8, 1-4.
227. (2013) Raising standards. Nat Neurosci 16, 517.
228. Cwiertniewicz J (2005) Introduction to the Good Laboratory Practice Regulations. Lab Anim (NY) 34, 29-32.
229. Liem FE, Lehr MJ (2008) Future issues including broadening the scope of the GLP principles. Ann Ist Super Sanita 44, 335-340.
230. Clary KM, Davey DD, Naryshkin S, Austin RM, Thomas N, Chmara BA, Sugrue C, Tworek J (2013) The role of monitoring interpretive rates, concordance between cytotechnologist and pathologist interpretations before sign-out, and turnaround time in gynecologic cytology quality assurance: Findings from the College of American Pathologists Gynecologic Cytopathology Quality Consensus Conference working group 1. Arch Pathol Lab Med 137, 164-174.
231. Bertram L, Tanzi RE (2009) Genome-wide association studies in Alzheimer's disease. Hum Mol Genet 18, R137-R145.
232. Piaceri I, Nacmias B, Sorbi S (2013) Genetics of familial and sporadic Alzheimer's disease. Front Biosci (Elite Ed) 5, 167-177.
233. Alzgene. Field synopsis of genetic association studies in AD, http://www. alzgene. org/, April 18, 2011, Accessed June 05, 2015.
234. Alagiakrishnan K, Gill SS, Fagarasanu A (2012) Genetics and epigenetics of Alzheimer's disease. Postgrad Med J 88, 522-529.
235. Emahazion T, Feuk L, Jobs M, Sawyer SL, Fredman D, St Clair D, Prince JA, Brookes AJ (2001) SNP association studies in Alzheimer's disease highlight problems for complex disease analysis. Trends Genet 17, 407-413.
236. Manolio TA, Collins FS, Cox NJ, Goldstein DB, Hindorff LA, Hunter DJ, McCarthy MI, Ramos EM, Cardon LR, Chakravarti A, Cho JH, Guttmacher AE, Kong A, Kruglyak L, Mardis E, Rotimi CN, Slatkin M, Valle D, Whittemore AS, Boehnke M, Clark AG, Eichler EE, Gibson G, Haines JL, Mackay TF, McCarroll SA, Visscher PM (2009) Finding the missing heritability of complex diseases. Nature 461, 747-753.
237. Bakulski KM, Rozek LS, Dolinoy DC, Paulson HL, Hu H (2012) Alzheimer's disease and environmental exposure to lead: The epidemiologic evidence and potential role of epigenetics. Curr Alzheimer Res 9, 563-573.
238. Zhang K, Schrag M, Crofton A, Trivedi R,Vinters H, Kirsch W (2012) Targeted proteomics for quantification of histone acetylation in Alzheimer's disease. Proteomics 12, 1261-1268.
239. Hu Y, Li L, Ehm MG, Bing N, Song K, Nelson MR, Talmud PJ, Hingorani AD, Kumari M, Kivimaki M, Xu CF, Waterworth DM,Whittaker JC, Abecasis GR, Spino C, Kang HM (2013) The benefits of using genetic information to design prevention trials. Am J Hum Genet 92, 547-557.
240. Swinney DC, Anthony J (2011) How were new medicines discovered? Nat Rev Drug Discov 10, 507-519.
241. Swinney DC (2013) Phenotypic vs. target-based drug discovery for first-in-class medicines. Clin Pharmacol Ther 93, 299-301.
242. Hurle MR, Yang L, Xie Q, Rajpal DK, Sanseau P, Agarwal P (2013) Computational drug repositioning: From data to therapeutics. Clin Pharmacol Ther 93, 335-341.
243. Lee JA, UhlikMT,Moxham CM, Tomandl D, Sall DJ (2012) Modern phenotypic drug discovery is a viable, neoclassic pharma strategy. J Med Chem 55, 4527-4538.
244. (2013) Q & A with Eli Lilly's Eric Siemers, http://www. biotech-now. org/health/2013/04/qa-witheli-lillys-eric-siemers#, April 23, 2013, Accessed June 05, 2015.
245. Cacabelos R (2008) Pharmacogenomics in Alzheimer's disease. Methods Mol Biol 448, 213-357.
246. Thompson PA, Wright DE, Counsell CE, Zajicek J (2012) Statistical analysis, trial design and duration in Alzheimer's disease clinical trials: A review. Int Psychogeriatr 24, 689-697.
247. Hobart J, Cano S, Posner H, Selnes O, Stern Y, Thomas R, Zajicek J, Alzheimer's Disease Neuroimaging I (2013) Putting the Alzheimer's cognitive test to the test II: Rasch Measurement Theory. Alzheimers Dement 9, S10-20.
248. Vellas B, Carrillo MC, Sampaio C, Brashear HR, Siemers E, Hampel H, Schneider LS, Weiner M, Doody R, Khachaturian Z, Cedarbaum J, Grundman M, Broich K, Giacobini E, Dubois B, Sperling R, Wilcock GK, Fox N, Scheltens P, Touchon J, Hendrix S, Andrieu S, Aisen P (2013) Designing drug trials for Alzheimer's disease: What we have learned from the release of the phase III antibody trials: A report from the EU/US/CTAD Task Force. Alzheimers Dement 9, 438-444.
249. Guidance for industry: Alzheimer's disease: Developing drugs for the treatment of early stage disease, U. S. Department of Health and Human Services. Food and Drug Administration. Center for Drug Evaluation and Research (CDER), http://www. fda. gov/downloads/drugs/guidance complianceregulatoryinformation/guidances/ucm338287. pdf, February 2013, Accessed June 05, 2015.
250. Watt AD, Crespi GA, Down RA, Ascher DB, Gunn A, Perez KA, McLean CA, Villemagne VL, ParkerMW, Barnham KJ, Miles LA (2014) Do current therapeutic anti-Abeta antibodies for Alzheimer's disease engage the target? Acta Neuropathol 127, 803-810.
251. Dubois B, Feldman HH, Jacova C, Cummings JL, Dekosky ST, Barberger-Gateau P, Delacourte A, Frisoni G, Fox NC, Galasko D, Gauthier S, Hampel H, Jicha GA, Meguro K, O'Brien J, Pasquier F, Robert P, Rossor M, Salloway S, Sarazin M, de Souza LC, Stern Y, Visser PJ, Scheltens P (2010) Revising the definition of Alzheimer's disease: A new lexicon. Lancet Neurol 9, 1118-1127.
252. Cronin-Stubbs D,DeKosky ST, Morris JC, EvansDA(2000) Promoting interactions with basic scientists and clinicians: The NIA Alzheimer's Disease Data Coordinating Center. Stat Med 19, 1453-1461.
253. Merlino G, Flaherty K, Acquavella N, Day CP, Aplin A, Holmen S, Topalian S, Van Dyke T, Herlyn M (2013) Meeting report: The future of preclinical mouse models in melanoma treatment is now. Pigment Cell Melanoma Res 26, E8-e14.
254. Insel TR, Voon V, Nye JS, Brown VJ, Altevogt BM, Bullmore ET, Goodwin GM, Howard RJ, Kupfer DJ, Malloch G, Marston HM, Nutt DJ, Robbins TW, Stahl SM, Tricklebank MD, Williams JH, Sahakian BJ (2013) Innovative solutions to novel drug development in mental health. Neurosci Biobehav Rev 37, 2438-2444.
255. Young JW, Powell SB, Risbrough V, Marston HM, Geyer MA (2009) Using the MATRICS to guide development of a preclinical cognitive test battery for research in schizophrenia. Pharmacol Ther 122, 150-202.
256. Lustig C,Kozak R, Sarter M,YoungJW, RobbinsTW(2013) CNTRICS final animal model task selection: Control of attention. Neurosci Biobehav Rev 37, 2099-2110.
257. Dawson GR, Craig KJ, Dourish CT (2011) Validation of experimental medicine methods in psychiatry: The P1vital approach and experience. Biochem Pharmacol 81, 1435-1441.
258. Geerts H, Roberts P, Spiros A, Carr R (2013) A strategy for developing new treatment paradigms for neuropsychiatric and neurocognitive symptoms in Alzheimer's disease. Front Pharmacol 4, 47.
259. Beekly DL, Ramos EM, Lee WW, Deitrich WD, Jacka ME, Wu J, Hubbard JL, Koepsell TD, Morris JC, Kukull WA (2007) The National Alzheimer's Coordinating Center (NACC) database: The Uniform Data Set. Alzheimer Dis Assoc Disord 21, 249-258.
260. Cummings JL, Ringman J, Metz K (2010) Mary S. Easton Center of Alzheimer's Disease Research at UCLA: Advancing the therapeutic imperative. J Alzheimers Dis 19, 375-388.
261. Snyder HM, Bain LJ, Egge R, Carrillo MC (2013) Alzheimer's disease public-private partnerships: A landscape of the global nonprofit community. Alzheimers Dement 9, 466-471.